Navigation Links
Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
Date:9/23/2013

0-542-0970; or JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, or via telephone at 415-835-8985; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or via telephone at 800-747-3924. 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Sangamo, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Proposes Public Offering Of Common Stock
2. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
3. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
4. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
9. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
10. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer famously ... found at the junctures where layers of different ... the interfaces between layers of metal oxides are ... favorites as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... they,ve been miniaturized to take up less space and ... data conversion electronics on the James Webb Space Telescope ... convert analog signals to digital signals and provide better ... "SIDECAR" have been miniaturized from a volume of about ...
... Feb. 20 Kensey Nash Corporation,(Nasdaq: KNSY ... clearance for an,important vessel wall detection technology from ... the guidance provided by the,Safe-Cross(R) RF CTO System. ... radio frequency (RF) energy to safely,cross and recanalize ...
... Calif., Feb. 20 5AM Ventures, specializing,in seed ... announced the expansion of the firm,s investment team ... Partner. 5AM Ventures,also announced the promotion of two ... and R. Andrew McMillan, PhD, to Principal. Drs. ...
Cached Biology Technology:Amazing minaturized 'SIDECAR' drives Webb telescope's signal 2Amazing minaturized 'SIDECAR' drives Webb telescope's signal 3Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 2Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 3Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 4Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 55AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 25AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 3
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a leading ... illness in very young and elderly populations. Despite ... host cells through the fusion protein RSV F, ... peptides that prevent bundle formation limit RSV infection ... to degradation. In this issue of the ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... University of North Carolina at Chapel Hill have purified a ... by reversing a molecular modification previously thought permanent. , In ... is able to remove a methyl group from histone H3, ... just last year, the addition of a methyl group to ...
... Hospital of Philadelphia leads a multi-center $6.7 million program ... Mental Health (NIMH) to explore a novel approach to ... and clinical trials in adult patients, the new grant ... immunodeficiency virus: sites on immune cells known as neurokinin-1 ...
... the work of machines that contain dozens of molecules, chiefly ... now have a nearly complete "parts list" of such machines; ... pieces go. A new study by scientists at the European ... some of the smallest and trickiest components in the cellular ...
Cached Biology News:Novel enzyme offers new look at gene regulation 2Federal grant funds research on novel HIV therapy 2Federal grant funds research on novel HIV therapy 3Many needles, many haystacks 2
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... cytopathic effect inhibition assays, also known as ... assay measures the antibody's ability to neutralize ... types include; tissue culture supernatents; serum and ... unit is defined as the quantity of ...
... Yeast nitrogen base (YNB) is a base ... yeast media. YNB contains ammonium sulfate but does ... single-use pouches are available. Each pouch contains ... for Pichia media or 1000 ml of 10X ...
... Stem Cell Identification Kit. ... a substrate for the ... that is highly expressed ... cells, making ALDH an ...
Biology Products: